Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Head-and-neck Cancer
68%
Cetuximab
59%
High-risk Human Papillomavirus (HR-HPV)
54%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
49%
Overall Survival
45%
Phase II Trial
43%
Head-and-neck
38%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Phase II Study
34%
Allogeneic Bone Marrow Transplantation
33%
Recurrent or Metastatic
33%
Granulocyte Colony-stimulating Factor (G-CSF)
33%
Cisplatin
29%
Graft-versus-host Disease (GvHD)
28%
Locally Advanced
26%
Tumor
25%
Squamous Cell Carcinoma of Head
24%
Confidence Interval
24%
Randomized Phase II Trial
22%
Radiation Therapy
21%
Induction Chemotherapy
21%
Peripheral Blood Stem Cells
20%
Total Body Irradiation
20%
High-dose Chemotherapy
19%
Recurrent Metastatic
19%
Nab-paclitaxel
19%
Pembrolizumab
17%
Docetaxel
17%
Cyclophosphamide
17%
Tumor Response
16%
Progression-free Survival
16%
Allogeneic Peripheral Blood Stem Cell Transplantation
16%
Distant Metastasis
16%
Bone Marrow Transplantation
16%
Clinical Outcomes
15%
Palbociclib
15%
Chemotherapy
15%
Metastatic Breast Cancer
14%
Soft Tissue Sarcoma
13%
Neoadjuvant
13%
Adjuvant Therapy
13%
Clinical Benefit
13%
Hazard Ratio
12%
Solid Tumors
12%
Peripheral Blood Stem Cell Transplantation
12%
Transplant Recipients
12%
Nasopharyngeal Carcinoma
12%
Allogeneic
12%
Treatment-related Mortality
12%
Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
72%
Neoplasm
51%
Head and Neck Cancer
49%
Wart Virus
46%
Overall Survival
43%
Disease
43%
Cetuximab
42%
Neck
35%
Oropharynx Squamous Cell Carcinoma
34%
Radiation Therapy
31%
Cisplatin
25%
Transplantation
24%
Squamous Cell Carcinoma
24%
Malignant Neoplasm
20%
Granulocyte Colony Stimulating Factor
18%
Progression Free Survival
18%
Oropharynx Carcinoma
18%
Pembrolizumab
17%
Chemotherapy
17%
Paclitaxel
16%
Soft Tissue Sarcoma
16%
Induction Chemotherapy
15%
P16
14%
Recurrent Disease
14%
Hazard Ratio
14%
Distant Metastasis
13%
Neutrophil
13%
Arm
12%
Allogenic Bone Marrow Transplantation
12%
Autologous Stem Cell Transplantation
12%
Breast Cancer
12%
Biological Marker
12%
Adjuvant Therapy
12%
Adverse Event
11%
Oropharyngeal Cancer
11%
Granulocyte
11%
Whole Body Radiation
11%
Chronic Myelogenous Leukemia
11%
Metastatic Breast Cancer
11%
Connective Tissue Cancer
11%
Immunotherapy
11%
Bone Cancer
10%
Disease Free Survival
10%
Allogeneic Peripheral Blood Stem Cell Transplantation
10%
Metastatic Carcinoma
10%
Oncology
10%
T Cell
10%
Conditioning
10%
Palbociclib
10%
Peripheral Blood Stem Cell
10%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Squamous Cell Carcinoma
72%
Cetuximab
53%
Overall Survival
41%
Neoplasm
40%
Head and Neck Cancer
36%
Disease
33%
Chemotherapy
30%
Squamous Cell Carcinoma
28%
Cisplatin
24%
Progression Free Survival
24%
Human Papillomavirus
24%
Paclitaxel
21%
Docetaxel
17%
Solid Malignant Neoplasm
17%
Cyclophosphamide
16%
Malignant Neoplasm
15%
Adverse Event
15%
Palbociclib
15%
High Dose Chemotherapy
15%
Soft Tissue Sarcoma
13%
Acute Graft Versus Host Disease
13%
Remission
12%
Chemoradiation Therapy
12%
Oropharynx Squamous Cell Carcinoma
11%
Breast Cancer
11%
Pembrolizumab
11%
Metastatic Breast Cancer
11%
Growth Factor
11%
Neutropenia
10%
Immunotherapy
10%
Monotherapy
9%
Oral Mucositis
9%
Doxorubicin
9%
Biological Marker
8%
Organ Toxicity
8%
Placebo
8%
Dacarbazine
8%
Antitumor Activity
8%
Granulocyte Colony Stimulating Factor
7%
Epidermal Growth Factor Receptor
7%
Cyclin Dependent Kinase 4
7%
Methotrexate
6%
Disease Exacerbation
6%
Fluorouracil
6%
Graft Versus Host Reaction
6%
Nasopharynx Carcinoma
6%
Alpha Interferon
6%
Chemotherapy Regimens
6%
Carboplatin
6%
Ciclosporin
6%